Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

BACKGROUND: In real-world practice, eribulin mesylate provides significant survival benefit, with a manageable safety profile in heavily pretreated patients with metastatic breast cancer (MBC). METHODS: In this prospective, open-label, multicentre, observational study we evaluated the effectiveness...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Adamo, Vincenzo, Ricciardi, Giuseppina Rosaria Rita, Giuffrida, Dario, Scandurra, Giuseppa, Russo, Antonio, Blasi, Livio, Spadaro, Pietro, Iacono, Carmelo, Soto Parra, Hector J., Savarino, Antonino, Ferraú, Francesco, Zerilli, Filippo, Verderame, Francesco, Butera, Alfredo, Santangelo, Carlo, Franchina, Veronica, Caruso, Michele
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6923689/
https://ncbi.nlm.nih.gov/pubmed/31903098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919895755
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados